Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.COV2.S and Influenza Vaccine Co-administration Study
NCT05091307Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19), sponsored by Janssen Pharmaceutical. Started Nov 2021; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05091307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091307.